ROS1 and non-small cell lung carcinoma: More recently, ROS proto-oncogene 1 (ROS1) rearrangements have also been identified in about 1–2% of non-squamous NSCLC, and although rare, their identification has become fundamental after target therapies, such as crizotinib, demonstrated robust antitumor activity [5].